Summit Climbs on Rumour of $15bn AstraZeneca Interest

Why AstraZeneca Stock Got Thumped on Thursday @themotleyfool #stocks $AZN $SMMT

Summit climbs on rumour of $15bn AstraZeneca interest

Is AstraZeneca about to join the ranks of pharma companies spending big bucks on PD(L)-1xVEGF bispecific antibodies for cancer?

Summit, AstraZeneca in talks over $15 billion cancer drug licensing deal, Bloomberg News reports

(Reuters) -AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as $15 billion, Bloomberg News reported on Thursday, citing people familiar with the matter.

Summit Is in Talks for $15 Billion Partnership With AstraZeneca

AstraZeneca Plc is discussing a partnership deal with Summit Therapeutics Inc. in which it could pay as much as $15 billion over time to license a lung-cancer drug, according to people familiar with the matter.